Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

A Phase II Study to Investigate the Efficacy and Safety of Eltrombopag in Combination with Dexamethasone As First-Line Treatment in Adult Patients with Newly Diagnosed Primary ITP (XPAG-ITP)

Axel Matzdorff, MDPhD, Mascha Binder, MD, Falk Nimmerjahn, PhD, Oliver Meyer, MD PhD, Mathias J. Rummel, MD PhD, Tamara Tesanovic, PhD, Tanja Sauer

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-134318

Published: 2020

Journal Articles

Minimal Residual Disease (MRD) Analysis Using Multiparametric Flow Cytometry (MFC) and Identification of Differences in Subpopulations Using Next Generation Sequencing (NGS) in the Bone Marrow (BM) of Multiple Myeloma (MM) Patients (pts)

Sandra M. Dold, MSc, BSc, Veronika Riebl, Dagmar Wider, Marie Follo, PhD, Stefan J. Mueller, Ingrid Bartsch, Milena Pantic, PhD, Cornelius Miething, MD, Chrissoula Kiote-Schmidt, K. Martin Kortüm, MD, Mihaela Zlei, Abdel Kareem Azab, PhD, Mascha Binder, MD, Justyna Rawluk, Justus Duyster, Prof., Robert Zeiser, MD, Ralph Wäsch, MD, Monika Engelhardt, MD

Blood (2018) 132 (Supplement 1): 3222.

https://doi.org/10.1182/blood-2018-99-112489

Published: 2018

Journal Articles

Final Analysis of the Dose Escalation, Expansion and Biomarker Correlations in the Ph I/II Trial BGBC003 with the Selective Oral AXL Inhibitor Bemcentinib (BGB324) in Relapsed/Refractory AML and MDS

Sonja Loges, MD, PhD, Michael Heuser, MD, Joerg Chromik, Carlos E Vigil, MD, Peter Paschka, MD, Isabel Ben-Batalla, PhD, Nuray Akyüz, David Micklem, Robert Holt, Anthony Brown, James Lorens, Murray Yule, Maxim Kebenko, MD, Melanie Janning, Mascha Binder, MD, Walter Fiedler, MD, Jorge E. Cortes, MD, Bjorn Gjertsen, MD PhD

Blood (2018) 132 (Supplement 1): 2672.

https://doi.org/10.1182/blood-2018-99-120380

Published: 2018

Journal Articles

The Orally Available Selective Axl Inhibitor BGB324 Induces Diversification of the Immune Repertoire and Specific Changes in Plasma Biomarker Profiles

Sonja Loges, MD PhD, Bjørn Tore Gjertsen, Michael Heuser, MD, Joerg Chromik, Isabel Ben-Batalla, Nuray Akyüz, David Micklem, Anthony Brown, James Lorens, Murray Yule, Maxim Kebenko, MD, Melanie Janning, Mascha Binder, MD, Walter Fiedler, MD, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 1375.

https://doi.org/10.1182/blood.V130.Suppl_1.1375.1375

Published: 2017

Journal Articles

BGB324, an Orally Available Selective Axl Inhibitor Exerts Anti-Leukemic Activity in the First-in-Patient Trial BGBC003 and Induces Unique Changes in Biomarker Profiles

Loges Sonja, Bjorn T. Gjertsen, Michael Heuser, Jörg Chromik, Isabel Ben Batalla, Nuray Akyüz, PhD, David Micklem, Anthony Brown, Jim Lorens, Maxim Kebenko, Melanie Janning, Mascha Binder, MD, Walter Fiedler, MD, Jorge E. Cortes, MD

Blood (2016) 128 (22): 592.

https://doi.org/10.1182/blood.V128.22.592.592

Published: 2016

Journal Articles

Effects on Survival and Neurocognitive Functions of Whole-Brain Radiotherapy (WBRT) and Autologous Stem Cell Transplantation (ASCT) as Consolidation Options after High-Dose Methotrexate-Based Chemoimmunotherapy in Patients with Newly Diagnosed Primary CNS Lymphoma (PCNSL): Results of the Second Randomization of the IELSG32 Trial

Andrés J.M. Ferreri, MD, Kate Cwynarski, MBBS, FRPATH, PhD, Elisa Jacobsen Pulczynski, MD, Christopher P. Fox, MBChB, PhD, Elisabeth Schorb, MD, Paul La Rosée, MD, Mascha Binder, MD, Alberto Fabbri, MD, Valter Torri, MD, Eleonora Minacapelli, MD, Monica Falautano, MD, Fiorella Ilariucci, MD, Achille Ambrosetti, MD, Alexander Röth, MD, Claire Jane Hemmaway, MD, Peter M Johnson, MA, MD, Kim Linton, MBChB, MRCP, PhD, Tobias Pukrop, MD, Jette Sonderskov Gorlov, MD, Monica Balzarotti, MD, Georg Hess, MD, Ulrich Keller, MD, Stephan Stilgenbauer, MD, Jens P. Panse, MD, Alessandra Tucci, MD, Lorella Orsucci, MD, Francesco Pisani, MD, Alessandro Levis, MD, Stefan W. Krause, MD, Hans-Joachim Schmoll, MD PhD, Bernd Hertenstein, MD, Mathias Rummel, MD PhD, Jeffery Smith, MD, Michael Pfreundschuh, MD, PhD, Giuseppina Cabras, MD, Francesco Angrilli, MD, Maurilio Ponzoni, MD, Martina Deckert, MD, Letterio S. Politi, MD, Jurgen Finke, MD, Michele Reni, MD, Franco Cavalli, Emanuele Zucca, Gerald Illerhaus, MD

Blood (2016) 128 (22): 511.

https://doi.org/10.1182/blood.V128.22.511.511

Published: 2016

Journal Articles

Opposite Effects of Bruton Tyrosine Kinase (BTK) Inhibitor Therapy with Ibrutinib and FCR Chemo-Immunotherapy on the Normal B Lymphocyte Repertoire in Patients with Chronic Lymphocytic Leukemia

Simon Schliffke, MD, Mariela Sivina, PhD, Ekaterina Kim, PhD, Benjamin Thiele, MD, Nuray Akyüz, PhD, Clemens Falker-Gieske, PhD, Toni Thenhausen, Artus Krohn-Grimberghe, PhD, Carsten Bokemeyer, MD, Nitin Jain, MD, Zeev Estrov, MD, Alessandra Ferrajoli, MD, William G. Wierda, MD PhD, Michael J. Keating, MD, Jan A. Burger, MD PhD, Mascha Binder, MD

Blood (2016) 128 (22): 4402.

https://doi.org/10.1182/blood.V128.22.4402.4402

Published: 2016

Journal Articles

High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Support for Relapsed or Refractory Primary CNS Lymphoma - a Prospective Multicentre Trial By the German Cooperative PCNSL Study Group

Blood (2016) 128 (22): 781.

https://doi.org/10.1182/blood.V128.22.781.781

Published: 2016

Journal Articles

Evidence for Autostimulatory Mechanisms in Chronic Lymphocytic Leukemia.

Martin Trepel, MD, PhD, Fabian Muller, MD, Mareike Frick, MD, Janina Rahlff, Claudia Wehr, Frederic Simon, PhD, Bernd Leistler, PhD, Hendrik Veelken, MD PhD, Roland H. Mertelsmann, MD, PhD, Mascha Binder, MD

Blood (2012) 120 (21): 2880.

https://doi.org/10.1182/blood.V120.21.2880.2880

Published: 2012

Journal Articles

Prognostic Impact of Physiological B-Cell Precursors (hematogones) in the Bone Marrow As Determined by Immunophenotyping in the Post-Transplant Period in Patients with AML

Ulrike Bacher, MD, Maximilian Christopeit, MD, Anneke Heiland, Mascha Binder, MD, Tatjana Zabelina, MD, Francis Ayuk, MD, Christiane Horn, Torsten Haferlach, MD, Carsten Bokemeyer, M.D., Nicolaus Kroeger, MD

Blood (2012) 120 (21): 1406.

https://doi.org/10.1182/blood.V120.21.1406.1406

Published: 2012

Journal Articles

Bone Marrow Cellularity, but Not Dysplasia, Is An Additional Prognostic Factor for Patients with Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation

Maximilian Christopeit, MD, Karolin Miersch, Evgeny Klyuchnikov, MD, Mascha Binder, MD, Francis Ayuk, MD, Tatjana Zabelina, MD, Philippe Schafhausen, MD, Carsten Bokemeyer, M.D., Torsten Haferlach, MD, Nicolaus Kroeger, MD, Ulrike Bacher, MD

Blood (2011) 118 (21): 4467.

https://doi.org/10.1182/blood.V118.21.4467.4467

Published: 2011

Journal Articles

B-Cell Receptor Recognition of Multiple Epitopes Correlates with An Aggressive Clinical Course of Chronic Lymphocytic Leukemia.

Mascha Binder, MD, Antje Jackst, Barbara Léchenne, Fabian Mueller, Hendrik Veelken, Roland H. Mertelsmann, MD, PhD, Martin Trepel

Blood (2009) 114 (22): 56.

https://doi.org/10.1182/blood.V114.22.56.56

Published: 2009

NARROW

A Phase II Study to Investigate the Efficacy and Safety of Eltrombopag in Combination with Dexamethasone As First-Line Treatment in Adult Patients with Newly Diagnosed Primary ITP (XPAG-ITP)

Minimal Residual Disease (MRD) Analysis Using Multiparametric Flow Cytometry (MFC) and Identification of Differences in Subpopulations Using Next Generation Sequencing (NGS) in the Bone Marrow (BM) of Multiple Myeloma (MM) Patients (pts)

Final Analysis of the Dose Escalation, Expansion and Biomarker Correlations in the Ph I/II Trial BGBC003 with the Selective Oral AXL Inhibitor Bemcentinib (BGB324) in Relapsed/Refractory AML and MDS

The Orally Available Selective Axl Inhibitor BGB324 Induces Diversification of the Immune Repertoire and Specific Changes in Plasma Biomarker Profiles

BGB324, an Orally Available Selective Axl Inhibitor Exerts Anti-Leukemic Activity in the First-in-Patient Trial BGBC003 and Induces Unique Changes in Biomarker Profiles

Opposite Effects of Bruton Tyrosine Kinase (BTK) Inhibitor Therapy with Ibrutinib and FCR Chemo-Immunotherapy on the Normal B Lymphocyte Repertoire in Patients with Chronic Lymphocytic Leukemia

High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Support for Relapsed or Refractory Primary CNS Lymphoma - a Prospective Multicentre Trial By the German Cooperative PCNSL Study Group

Evidence for Autostimulatory Mechanisms in Chronic Lymphocytic Leukemia.

Prognostic Impact of Physiological B-Cell Precursors (hematogones) in the Bone Marrow As Determined by Immunophenotyping in the Post-Transplant Period in Patients with AML

Bone Marrow Cellularity, but Not Dysplasia, Is An Additional Prognostic Factor for Patients with Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation

B-Cell Receptor Recognition of Multiple Epitopes Correlates with An Aggressive Clinical Course of Chronic Lymphocytic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only